Dealing with lung cancer in the COVID-19 scenario (A review).
angiotensin-converting enzyme 2
coronavirus disease 2019
lung cancer
non-small cell lung cancer
severe acute respiratory syndrome coronavirus 2
small-cell lung cancer
transmembrane protease serine 2
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
30
06
2020
accepted:
12
12
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
9
1
2021
Statut:
ppublish
Résumé
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused the coronavirus disease 2019 (COVID-19), first appeared in December 2019 in Wuhan (China) and quickly spread worldwide and has since been assigned a pandemic status. This affected the worlds' social interactions, including within medical practices, thus interfering with routine treatments for a variety of diseases including cancer. Different studies have addressed the fact that patients with cancer are often immunocompromised, making them more susceptible to infections. Since COVID-19 frequently causes respiratory distress, patients with lung cancer are considered to be a high-risk group. Genes that have been indicated to mediate viral entry into host cells such as angiotensin-converting enzyme 2 and transmembrane protease serine 2 are expressed in the lung tissue, a fact that could partially explain COVID-19 pathogenesis and lung involvement. Therefore, the current study offers a disease overview including molecular aspects behind the infection and provide a perspective on already published Chinese data plus recommendations for the management of lung cancer patients according to the two main lung cancer types and stages: non-small cell lung cancer and small cell lung cancer. This review aimed to add to the collective effort of selecting the most appropriate guidelines to follow for the treatment of these patients.
Identifiants
pubmed: 33414908
doi: 10.3892/mco.2020.2189
pii: MCO-0-0-02189
pmc: PMC7784234
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
27Informations de copyright
Copyright: © Aran et al.
Références
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
F1000Res. 2014 Sep 12;3:221
pubmed: 25469231
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
Front Pediatr. 2020 Apr 23;8:206
pubmed: 32391299
Cell Res. 2008 Feb;18(2):290-301
pubmed: 18227861
J Oral Sci. 2020;62(3):350-351
pubmed: 32581183
Antiviral Res. 2020 Apr;176:104742
pubmed: 32057769
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12543-7
pubmed: 16116101
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Front Oncol. 2020 Apr 22;10:665
pubmed: 32391282
J Transl Med. 2020 Apr 6;18(1):154
pubmed: 32252784
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
J Med Virol. 2020 Jul;92(7):719-725
pubmed: 32170865
J Pain Symptom Manage. 2020 Jul;60(1):e12-e14
pubmed: 32240756
Cancers (Basel). 2020 Aug 05;12(8):
pubmed: 32764454
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
J Infect Dis. 2020 Jul 23;222(4):556-563
pubmed: 32526012
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Traffic. 2016 Jun;17(6):593-614
pubmed: 26935856
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Zhongguo Fei Ai Za Zhi. 2020 Feb 20;23(3):133-135
pubmed: 32077440
J Intern Med. 2020 Aug;288(2):192-206
pubmed: 32348588
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
J Clin Virol. 2020 May;126:104345
pubmed: 32278298
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Infect Dis. 2020 Jul;20(7):758-759
pubmed: 32330441
Mol Cancer. 2020 Apr 28;19(1):80
pubmed: 32345328
EMBO J. 2020 May 18;39(10):e105114
pubmed: 32246845
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Transl Lung Cancer Res. 2018 Jun;7(3):220-233
pubmed: 30050761
Infect Dis Poverty. 2020 Apr 28;9(1):45
pubmed: 32345362
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Radiology. 2020 Jun;295(3):715-721
pubmed: 32053470
J Thorac Oncol. 2020 Jul;15(7):1137-1146
pubmed: 32360578
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711